Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
Natalie Gukasyan, Sandeep M. Nayak
Transcultural Psychiatry January 26, 2021 DOI: 10.1177/1363461520983684 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Placebo-controlled Peer reviewed |
|---|---|
| Citations | 148 |
| Key points | Argues that common factors theory can help explain contextual effects (set and setting) in psychedelic-assisted treatment and that four shared factors—the therapeutic relationship, healing setting, rationale or myth, and ritual—may contribute to therapeutic outcomes. |
Abstract
Psychedelic-assisted treatment is at first glance markedly different in structure and approach from mainstream forms of psychotherapy in the West. A major criticism of clinical psychedelic research rests on the difficulty of executing placebo-controlled studies and distinguishing drug effects from those of the psychotherapeutic container in which psychedelics are typically presented. Detractors also tend to find fault in spiritual or mystical themes that often arise in the context of psychedelic use. Common factors theory of psychotherapy is a useful and extensively studied framework that can help make sense of these issues, and has much to contribute to our understanding of contextual effects that are often discussed in psychedelic literature as "set and setting." In this article, we examine four major contextual "common factors" shared by various healing traditions: 1) the therapeutic relationship; 2) the healing setting; 3) the rationale, conceptual scheme, or myth; and 4) the ritual. We explain how these factors show up in psychedelic-assisted treatment and how they may contribute to therapeutic effects. Lastly, we discuss the implications of these factors for the concept of placebo, and for future research.
Citations in the library
Cited by 121
- Blinding and expectancy confounds in psychedelic randomized controlled trials Expert Review of Clinical Pharmacology May 26, 2021
- Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials Psychopharmacology April 1, 2022
- Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial Journal of Psychopharmacology March 20, 2023
- Treatment with psychedelics is psychotherapy: beyond reductionism The Lancet Psychiatry December 12, 2023
- Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology September 5, 2022
and 116 more in the library
Cites 39
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 34 more in the library